Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott Lambert Carter, Ph.D.

Co-Author

This page shows the publications co-authored by Scott Carter and Eliezer Van Allen.
Connection Strength

2.326
  1. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571.
    View in: PubMed
    Score: 0.212
  2. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193.
    View in: PubMed
    Score: 0.190
  3. Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.190
  4. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
    View in: PubMed
    Score: 0.180
  5. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
    View in: PubMed
    Score: 0.177
  6. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373.
    View in: PubMed
    Score: 0.175
  7. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget. 2016 Aug 16; 7(33):52888-52899.
    View in: PubMed
    Score: 0.173
  8. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63.
    View in: PubMed
    Score: 0.159
  9. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44.
    View in: PubMed
    Score: 0.159
  10. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
    View in: PubMed
    Score: 0.148
  11. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan; 4(1):94-109.
    View in: PubMed
    Score: 0.143
  12. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
    View in: PubMed
    Score: 0.056
  13. Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clin Cancer Res. 2019 08 15; 25(16):5135-5142.
    View in: PubMed
    Score: 0.053
  14. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017; 12(6):e0178189.
    View in: PubMed
    Score: 0.046
  15. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222.
    View in: PubMed
    Score: 0.044
  16. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  17. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73.
    View in: PubMed
    Score: 0.039
  18. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
    View in: PubMed
    Score: 0.038
  19. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
    View in: PubMed
    Score: 0.036
  20. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.034
  21. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.